dihydroergocornine

Absorption

Dihydroergocornine absorption in man after oral administration is very rapid when compared to the mixture or most of the components. The time to reach maximum plasma concentration or 0.57 ng-eq/ml is 1.4 hours. It presents an absorption half-life of 0.32 hours. The absorption percentage is of about 25% which corresponds to the registered absorption presented in the ergoloid mixture. To know more about the pharmacokinetics please visit Ergoloid mesylate.

Toxicity

Dihydroergocornine effect on fertility was tested in preclinical studies. The reported effect was a decreased weight gain in neonates. Overdosing has also been reported to present effects of fall of blood pressure and a decrease in heart rate to 13 beats per minute. To know more about the pharmacokinetics please visit Ergoloid mesylate.

The Uses of dihydroergocornine

9,10-Dihydroergocornine is used as TAAR receptor agonist for treatment of alopecia.

Indications

To know more about the approved indications please visit Ergoloid mesylate

Background

Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects. It is an artificial derivative of the crude extract of ergot and later purified, ergocornine. The formation of dihydroergocornine implies the hydrogenation of the double bonds in the lysergic acid. Dihydroergocornine presents a formula of 9,10 alpha-dihydro-12'-hydroxy-2',5'alpha-bis(1-methylethyl)-ergotaman-3',6',18-trione. It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to Ergoloid mesylate

Definition

ChEBI: Ergocornine in which a single bond replaces the double bond between positions 9 and 10.

Pharmacokinetics

It is reported that dihydroergocornine administration, in non-toxic doses, presents sympatholytic and hypotensive properties which are observed as a significantly decreased mean arterial pressure. In the brain, the activity of dihydroergocornine was observed as a decrease in cerebral blood flow, cerebral vascular resistance and oxygen uptake. The effect in the brain seems to allow a cerebral metabolic homeostasis. To know more about the pharmacology please visit Ergoloid mesylate

Metabolism

The biotransformation of dihydroergocornine occurs via oxidation and cleavage of the proline in the peptide portion of the molecule as well as by the splitting of the amide bond yielding dihydrolysergic acid amide. Some of the derivate metabolites retain the essential ring structure of the ergot alkaloid. To know more about the pharmacokinetics please visit Ergoloid mesylate.